Cytek Biosciences has seen its fair value estimate adjusted from US$5.75 to US$6.00, placing the stock in a slightly higher US$5 to US$6 price target framework. Analysts attribute this shift to a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results